Jilly F. Evans

发表

Formylpeptide receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

Marc Parmentier, Charles N. Serhan, Takao Shimizu, 2019, IUPHAR/BPS Guide to Pharmacology CITE.

Crystal Structure of Inhibitor-Bound Human 5-Lipoxygenase-Activating Protein

Jilly F. Evans, Shihua Xu, A. Ferguson, 2007, Science.

Identification and isolation of a membrane protein necessary for leukotriene production

Jilly F. Evans, Jacques Yves Gauthier, Irving S. Sigal, 1990, Nature.

International Union of Pharmacology XLIV. Nomenclature for the Oxoeicosanoid Receptor

Takao Shimizu, Jilly F. Evans, Takehiko Yokomizo, 2004, Pharmacological Reviews.

Identification of receptors for neuromedin U and its role in feeding

Christopher P. Austin, Jilly F. Evans, C. Thomas Caskey, 2000, Nature.

Formylpeptide receptors in GtoPdb v.2021.2

Jilly F. Evans, S. Dahlén, M. Parmentier, 2021 .

CrossTORC and WNTegration in Disease: Focus on Lymphangioleiomyomatosis

Jilly F. Evans, V. Krymskaya, K. Obraztsova, 2021, International journal of molecular sciences.

Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.

Jilly F. Evans, C. Kelly, S. Kargman, 2003, Cancer research.

International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors

Jilly F. Evans, J. Drazen, S. Dahlén, 2003, Pharmacological Reviews.

Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells.

Jilly F. Evans, R. Vollandt, C. Funk, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Transgenic smooth muscle expression of the human CysLT1 receptor induces enhanced responsiveness of murine airways to leukotriene D4.

Jilly F. Evans, R. Panettieri, C. Funk, 2004, American journal of physiology. Lung cellular and molecular physiology.

Leukotriene B4 Strongly Increases Monocyte Chemoattractant Protein-1 in Human Monocytes

Jilly F. Evans, M. Struthers, F. Ujjainwalla, 2004, Arteriosclerosis, thrombosis, and vascular biology.

The cysteinyl leukotriene receptors.

Jilly F. Evans, 2002, Prostaglandins, leukotrienes, and essential fatty acids.

Cysteinyl leukotriene receptors.

Jilly F. Evans, 2003, Prostaglandins & other lipid mediators.

The nuclear membrane organization of leukotriene synthesis

Jilly F. Evans, Phillip B. Jones, B. Hyman, 2008, Proceedings of the National Academy of Sciences.

Pharmacological Characterization of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103), a Novel Selective 5-Lipoxygenase-Activating Protein Inhibitor That Reduces Acute and Chronic Inflammation

Jilly F. Evans, D. Lorrain, C. King, 2009, Journal of Pharmacology and Experimental Therapeutics.

The Cysteinyl Leukotriene (CysLT) Pathway in Allergic Rhinitis

Jilly F. Evans, 2005 .

Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation.

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, European journal of pharmacology.

Cloning and characterization of human cysteinyl leukotriene receptors

Jilly F. Evans, 2002 .

Localization and upregulation of cysteinyl leukotriene-1 receptor in asthmatic bronchial mucosa.

Jilly F. Evans, K. Guntupalli, Jie Zhu, 2005, American journal of respiratory cell and molecular biology.

Montelukast Use Decreases Cardiovascular Events in Asthmatics

Jilly F. Evans, A. Sala, G. Rovati, 2020, Frontiers in Pharmacology.

Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor.

Jilly F. Evans, C. King, J. Bentley, 2013, British journal of clinical pharmacology.

Pharmacological Blockade of the DP2 Receptor Inhibits Cigarette Smoke-Induced Inflammation, Mucus Cell Metaplasia, and Epithelial Hyperplasia in the Mouse Lung

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, Journal of Pharmacology and Experimental Therapeutics.

5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Journal of medicinal chemistry.

Cysteinyl leukotriene 1 receptor expression associated with bronchial inflammation in severe exacerbations of COPD.

Jilly F. Evans, Jie Zhu, P. Jeffery, 2012, Chest.

DP2 (CRTh2) Antagonism Reduces Ocular Inflammation Induced by Allergen Challenge and Respiratory Syncytial Virus

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, International Archives of Allergy and Immunology.

Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation.

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, European journal of pharmacology.

5-Lipoxygenase-activating Protein (FLAP) Inhibitors Are Superior To 5-lipoxygenase (5-LO) Inhibitors For Inhibition Of Leukotriene Synthesis In Rat Lung

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, ATS 2010.

Characterization of the human cysteinyl leukotriene CysLT1 receptor

Jilly F. Evans, C. Austin, B. Connolly, 1999, Nature.

5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)-A potent FLAP inhibitor suitable for topical administration.

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, Bioorganic & medicinal chemistry letters.

A Novel 5-Lipoxygenase-Activating Protein Inhibitor, AM679, Reduces Inflammation in the Respiratory Syncytial Virus-Infected Mouse Eye

Jilly F. Evans, D. Lorrain, S. Barik, 2009, Clinical and Vaccine Immunology.

Bestatin inhibits covalent coupling of [3H]LTA4 to human leukocyte LTA4hydrolase

Jilly F. Evans, S. Kargman, 1992, FEBS letters.

5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, Bioorganic & medicinal chemistry letters.

5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).

Jilly F. Evans, D. Lorrain, P. Prasit, 2009, Journal of medicinal chemistry.

Evaluation of endo- and exo-aryl-substitutions and central scaffold modifications on diphenyl substituted alkanes as 5-lipoxygenase activating protein inhibitors.

Jilly F. Evans, L. Chu, F. Ujjainwalla, 2012, Bioorganic & medicinal chemistry letters.

Expression, purification and crystallization of human 5-lipoxygenase-activating protein with leukotriene-biosynthesis inhibitors.

Jilly F. Evans, A. Ferguson, Shihua Xu, 2007, Acta crystallographica. Section F, Structural biology and crystallization communications.

The membrane organization of leukotriene synthesis.

Jilly F. Evans, B. Hyman, B. Bacskai, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis

Jilly F. Evans, Andiliy G. Lai, C. King, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Bioorganic & medicinal chemistry letters.

Pharmacology of AM211, a Potent and Selective Prostaglandin D2 Receptor Type 2 Antagonist That Is Active in Animal Models of Allergic Inflammation

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Journal of Pharmacology and Experimental Therapeutics.

Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Bioorganic & medicinal chemistry letters.

Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.

Jilly F. Evans, D. Lorrain, P. Prasit, 2009, Bioorganic & medicinal chemistry letters.

Effects of prolactin on TSC2-null Eker rat cells and in pulmonary lymphangioleiomyomatosis.

Jilly F. Evans, J. Moss, M. Stylianou, 2010, American journal of respiratory and critical care medicine.

Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC).

Jilly F. Evans, Z. Zou, A. Floreani, 2016, Autoimmunity reviews.

Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor

Jilly F. Evans, V. Krymskaya, A. Mukhitov, 2019, Biomolecules.

Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7

Jilly F. Evans, J. Drazen, S. Dahlén, 2014, British journal of pharmacology.

Leukotriene receptors (version 2020.3) in the IUPHAR/BPS Guide to Pharmacology Database

Jilly F. Evans, J. Drazen, S. Dahlén, 2020 .

Leukotriene receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

Jilly F. Evans, J. Drazen, S. Dahlén, 2019, IUPHAR/BPS Guide to Pharmacology CITE.

Identification and Characterization of Novel Mammalian Neuropeptide FF-like Peptides That Attenuate Morphine-induced Antinociception*

Jilly F. Evans, T. Mcdonald, Hong B. Yu, 2001, The Journal of Biological Chemistry.

International Union of Basic and Clinical Pharmacology. LXXXIV: Leukotriene Receptor Nomenclature, Distribution, and Pathophysiological Functions

Jilly F. Evans, J. Drazen, S. Dahlén, 2011, Pharmacological Reviews.

Characterization of the Human Cysteinyl Leukotriene 2 Receptor*

Jilly F. Evans, B. O'dowd, R. Stocco, 2000, The Journal of Biological Chemistry.

A cysteinyl leukotriene 2 receptor variant is associated with atopy in the population of Tristan da Cunha.

Jilly F. Evans, Arthur S Slutsky, K. Siminovitch, 2003, Pharmacogenetics.

Differential Leukotriene Receptor Expression and Calcium Responses in Endothelial Cells and Macrophages Indicate 5-Lipoxygenase–Dependent Circuits of Inflammation and Atherogenesis

Jilly F. Evans, R. Heller, R. Spanbroek, 2003, Arteriosclerosis, thrombosis, and vascular biology.

Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2)

Bruno C. Hancock, Jilly F. Evans, M. Taketo, 1996, Cell.

mTORC1 activation in lung mesenchyme drives sex- and age-dependent pulmonary structure and function decline

Jilly F. Evans, Shanru Li, E. Morrisey, 2020, Nature Communications.

What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases.

Jilly F. Evans, A. Ferguson, R. Mosley, 2008, Trends in pharmacological sciences.

Seeing the future of bioactive lipid drug targets.

Jilly F. Evans, J. Hutchinson, 2010, Nature chemical biology.

The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm

Jilly F. Evans, D. Rader, Lei Zhao, 2004, Nature Medicine.

Chemoprevention of intestinal polyposis in the APCΔ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor

Jilly F. Evans, M. Taketo, S. Kargman, 2000, American Journal of Gastroenterology.

Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding

Jilly F. Evans, J. Hutchinson, Jeffrey M. Schaub, 2015, Molecular Pharmacology.

Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding s

Jilly F. Evans, J. Hutchinson, G. Bain, 2015 .

Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX.

Jilly F. Evans, C. King, J. Hutchinson, 2017, ACS medicinal chemistry letters.

Syndecan-2: Old Player in a New Field

Jilly F. Evans, V. Krymskaya, K. Obraztsova, 2019, American journal of respiratory cell and molecular biology.

Identification of a GABAB Receptor Subunit, gb2, Required for Functional GABAB Receptor Activity*

Jilly F. Evans, L. F. Kolakowski, T. Bonner, 1999, The Journal of Biological Chemistry.

Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).

Jilly F. Evans, Andiliy G. Lai, D. Mackenna, 2017, Journal of medicinal chemistry.

DP2 Receptor Antagonists: Novel Therapeutic Target for COPD

Jilly F. Evans, D. Lorrain, K. Stebbins, 2010 .

Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells

Jilly F. Evans, B. Himes, M. Bartolomei, 2018, PloS one.

Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer.

S Jothy, Jilly F. Evans, J. Evans, 1995, Cancer research.

Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells.

Jilly F. Evans, J. Falgueyret, D. Riendeau, 1996, Biochemical pharmacology.

Receptor for motilin identified in the human gastrointestinal system.

Jilly F. Evans, Ploeg, C. Austin, 1999, Science.

Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14.

Jilly F. Evans, C. Austin, T. Mcdonald, 1999, Biochemical and biophysical research communications.

Discovery and mapping of ten novel G protein-coupled receptor genes.

Jilly F. Evans, B. O'dowd, J. Evans, 2001, Gene.

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.

Jilly F. Evans, R. Chopra, P. Schafer, 2014, Cellular signalling.

Trust Guideline for the Management of Incidents which have the potential to transmit Blood Borne Viruses A clinical guideline recommended for use

Jilly F. Evans, S. Dervisevic, T. Daynes, 2015 .

Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7

Jilly F. Evans, J. Drazen, S. Dahlén, 2014, British journal of pharmacology.

Pharmacokinetic and Pharmacodynamic Characterization of an Oral Lysophosphatidic Acid Type 1 Receptor-Selective Antagonist

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Journal of Pharmacology and Experimental Therapeutics.

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.

Jilly F. Evans, R. Chopra, P. Schafer, 2014, Cellular signalling.

Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Bioorganic & medicinal chemistry letters.

Mouse by Rofecoxib , a Specific Cyclooxygenase-2 Inhibitor 716 ∆ Apc Chemoprevention of Intestinal Polyposis in the Updated Version

Jilly F. Evans, M. Taketo, S. Kargman, 2001 .

Pharmacokinetic and Pharmacodynamic Characterization of an Oral Lysophosphatidic Acid Type 1 Receptor-Selective Antagonist

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Journal of Pharmacology and Experimental Therapeutics.

Mouse by Rofecoxib , a Specific Cyclooxygenase-2 Inhibitor 716 ∆ Apc Chemoprevention of Intestinal Polyposis in the Updated Version

Jilly F. Evans, M. Taketo, S. Kargman, 2001 .